Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06515184 · ClinicalTrials.gov registry record · Phase 3
Coenzyme Q10 for Gulf War Illness: A Replication Study
A Phase 3 study of Gulf War Syndrome and Persian Gulf Syndrome, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 1
- Study location
NCT06515184 is a Phase 3 study of Gulf War Syndrome and Persian Gulf Syndrome that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 192 participants, above the 111-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (73% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06515184, a Phase 3 study of Gulf War Syndrome and Persian Gulf Syndrome, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Conditions Studied
Interventions
- DRUG PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
- DRUG PharmaNord Placebo
Study Locations (1)
California
- UC San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2024-09-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06515184
The ClinicalTrials.gov registry entry for NCT06515184 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 111-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (73% higher). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gulf War Syndrome appearing as the primary indexed condition, and to 2 interventions - of which PharmaNord Bio-Quinone Active CoQ10 Gold 100mg is the first listed.
NCT06515184 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06515184 about?
NCT06515184 is a clinical study titled "Coenzyme Q10 for Gulf War Illness: A Replication Study". The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
What is the current status of trial NCT06515184?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2024-09-13. Estimated completion is 2027-12.
What conditions does trial NCT06515184 study?
This clinical trial studies the following conditions: Gulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorder, Respiratory Chain.
What interventions are being tested in trial NCT06515184?
The interventions under investigation include: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg (DRUG), PharmaNord Placebo (DRUG).
Who is sponsoring clinical trial NCT06515184?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06515184 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gulf War Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Confirmation of Diet as a Treatment for Gulf War Illness
RECRUITING · Phase 3
-
Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
RECRUITING · Phase 1
-
Validating Gulf War Illness Blood Biomarkers
RECRUITING
-
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
RECRUITING · Phase 2
-
Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness
RECRUITING · NA
-
GWICTIC: NAC Mechanistic Study in Gulf War Veterans
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.